← Eichor
Study identifier: NCT05697562 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Evaluation of Superior Rectal Arterial Embolization in Hemorrhoidal Disease

Condition: Hemorrhoids  ·  Sponsor: Universitair Ziekenhuis Brussel

PhaseNA
Planned participants80
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

SRAE is a promising treatment of bleeding HD as a minimally invasive approach without sphincter damage nor direct mucosal anorectal trauma. Feasibility, efficacy and safety were studied in several trials. A randomized controlled study should confirm the benefits of this technique and will define its therapeutic role in HD. Embolization and DG-HAL are based on the same concept of vascular occlusion of hemorrhoidal branches of the rectal artery. Furthermore, DG-HAL and RBL are equally effective procedures. The assumption is that treatment with SRAE is not inferior in comparison to RBL or DG HAL in respectively patients without or with antiplatelet/anticoagulation therapy in terms of symptom control and bleeding (non-inferiority study).

This description comes directly from the study's public registry record.

Talk to the study team

Magali Surmont  ·  +32 2 477  ·  magali.surmont@uzbrussel.be

Virgini Van Buggenhout  ·  +32 2 477  ·  virgini.vanbuggenhout@uzbrussel.be

Always discuss trial participation with your own doctor first.

Locations (1)

UZ BrusselJette, BelgiumRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05697562